Increased VEGF expression is found in several pathologies characterized by abnormal angiogenesis. Previous studies have shown that the transcription factor STAT3 mediates VEGF gene transcription and its activation. In this study, Western analysis and confocal immunocytochemistry were used to examine STAT3 activation in retinal microvascular endothelial cells (BREC). We found that VEGF rapidly induces STAT3 tyrosine phosphorylation and nuclear translocation. Immunoprecipitation studies also showed that VEGF forms a complex with VEGFR2 only in BREC and not in aortic macrovascular endothelial cells (BAEC). In addition, quantitative real-time RT-PCR analysis of VEGF-induced VEGF expression showed a significant increase in specific mRNA formation only in BREC and not in BAEC, and this effect was significantly reduced by antisense-mediated reduction of STAT3 expression. Furthermore, studies conducted in human dermal microvascular endothelial cells (HDMEC) showed that, in this endothelial cell type, VEGF autocrine expression is also accompanied by STAT3 activation as in BREC. In this study we showed that VEGF can differentially induce STAT3 activation in micro-versus macro-vascular endothelial cells and that this effect is linked to VEGFR2/STAT3 complex formation, which correlates with VEGF autocrine ability to stimulate its own gene expression.
A wide variety of normal and tumoral cells can induce VEGF expression in response to several stimuli, the most physiological of which is hypoxia (7, 8) . Decreased oxygen levels trigger VEGF expression by inducing hypoxia-inducible factor-1 α (HIF-1α) transcriptional activity (10, 11) . Most recently, a number of reports have shown that the transcription factor signal transducer and activator of transcription 3 (STAT3) plays a pivotal role in angiogenesis by mediating VEGF expression (7, (12) (13) (14) (15) . STAT3 constitutive activation has been shown to correlate with increased rate of VEGF expression and angiogenesis in myocardial tissue and in a number of tumoral cells and human cancers (7, (12) (13) (14) (15) . Moreover, STAT3 binding sites have been identified in the VEGF promoter, and mutations of these regions can block specific mRNA transcription (15) . STAT3 belongs to a family of latent cytoplasmic transcription factors that regulates gene expression associated with cellular growth responses to cytokines, interferons, and growth factors (16) (17) (18) . STAT3 activity is regulated by posttranslational modifications involving phosphorylation of specific conserved tyrosine residues and active nuclear translocation followed by DNA binding and transcriptional activation of the target genes (16, 17) . Finally, STAT3 has also been shown to participate in cell cycle regulation, apoptosis, and cellular transformation, and lack of its expression during embryogenesis is lethal (18) (19) (20) (21) .
We have reported previously that in bovine aortic macrovascular endothelial cells (BAEC) VEGF promotes the activation of the STAT pathway via the VEGF receptor 2 (VEGFR2; 22) . We found a rapid tyrosine phosphorylation and nuclear translocation of STAT1 and STAT6. However, the tyrosine phosphorylation of STAT3 was significantly delayed with no nuclear translocation, thus indicating a lack of STAT3-dependent transcriptional events (22) . Because angiogenesis primarily targets microcapillary structures and little is known about how angiogenic factors can selectively exert their effects on microvascular endothelium, we wanted to determine whether STAT3 could be differentially activated by VEGF in microvascular endothelial cells and whether this could result in different profiles of VEGF expression.
MATERIALS AND METHODS

Materials
Unless otherwise specified, all the tissue culture reagents were from Invitrogen (Carlsbad, CA). Fetal calf serum was from Hyclone (Logan, UT). The CS-C medium was from Cells System Corp. (Kirkland, WA). Bacto-gelatin was from Sigma-Aldrich (St. Louis, MO). The polyclonal antibodies for STAT3 and VEGFR2, the monoclonal antibody anti-phosphotyrosine (PY99), as well as the protein A/G agarose beads were all from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant human VEGF 165 (VEGF) was from R&D System Inc. (Minneapolis, MN). Monoclonal antibody anti-STAT3 was from BD-Transduction Labs (San Diego, CA). Antiphosphotyrosine-STAT3 was obtained from Cell Signaling Technology (Beverly, CA). The polyclonal antibody anti actin was from Sigma-Aldrich. The ECL chemiluminescence detection assay was from Amersham Biosciences (Piscataway, NJ). The stripping solution was Restore from Pierce (Rockford, IL).
Cell culture
Bovine aortic and retinal endothelial cells were isolated from intact tissues following previously established protocols (22, 23) . BAEC were cultured in medium M199 in the presence of 10% FCS, glutamine, penicillin/streptomycin, non-essential amino acid, and vitamin mixture. BREC, plated on gelatin-coated dishes, were also cultured in medium M199 containing glutamine, penicillin/streptomycin, and supplemented with 10% FCS and 10% CS-C. Human adult microvascular dermal cells (HDMEC) were purchased from Cambrex (Walkersville, MD) and cultured in the same conditions as the BREC. BAEC were used between passage 3 and 5, BREC were used between passage 4 and 9, and HDMEC were used at the second passage after arrival. The cells were stimulated with 10 or 25 ng/ml VEGF for established time points (see Results).
Immunoprecipitation and immunoblotting analysis
BAEC, BREC, and HDMEC were cultured to 85% confluency and then switched to serum-free medium for 16-18 h. After stimulation with VEGF for different times, the cells were lysed with a lysis buffer containing 20 mM Tris-HCl (pH 7.4), 2.5 mM EDTA, 50 mM NaF, 10 mM Na 4 P 2 O 7 , 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1% sodium deoxycholate, 1 mM PMSF, and 2 mM Na 3 VO 4 . Immunoprecipitation and Western blotting analyses were performed as described previously (22, 23) . For the co-immunoprecipitation studies the cells were lysed with the following buffer: 25 mM Tris-HCl (pH 7.4), 2.5 mM EDTA, 50 mM NaF, 10 mM Na 4 P 2 O 7 , 1% Triton X-100, 1 mM PMSF, and 2 mM Na 3 VO 4 .
Nuclear fractionation
To identify STAT proteins in the nuclear compartment, we immunoblotted nuclear extracts from BREC after VEGF treatment and from untreated cells as control. The nuclear extracts were obtained from nuclei purified over a 350 mM sucrose cushion, as described (22, 23) . Nuclear extracts (25 µg protein/sample) were then subjected to SDS/PAGE and immunoblotted by using anti-STAT3 antibodies.
Immunocytochemistry
STAT3 nuclear mobilization has been also evaluated by confocal immunocytochemistry following a previously published protocol (22, 23) . BREC were plated on gelatin-coated chamber slides (Nalge Nunc International, Naperville, IL) and subjected to VEGF treatments as indicated in Results. The cells were then fixed in ethanol: acetic acid: water (9:0.5:0.5) for 30 min on ice and blocked for 30 min with 1% normal goat serum (Sigma-Aldrich). The primary antibody, directed against STAT3, was then applied and left to react overnight at 4°C in a humidified chamber. Anti-mouse FITC-conjugated secondary antibody (Oregon green from Molecular Probes, Eugene, CA) was incubated for 45 min at room temperature. For nuclear counterstaining, we used propidium iodide (Molecular Probes, Eugene, CA). The stained cells were analyzed by a confocal microscope (LSM 510 META, Carl Zeiss, Thornwood, NY), and intranuclear localization of STAT3-specific immunoreactivity was determined by producing confocal sections along the yz and xz optical planes.
Antisense experiments
We followed an established protocol that consists of hypertonic loading (20% mannitol in serum free M199) of phosphorothioate oligonucleotides (24) . These oligonucleotides were obtained from the Molecular Biology Core Laboratory of the Medical College of Georgia. The STAT3 antisense oligonucleotides were directed against the translational starting site (AUG codon) of the human STAT3 gene (25) . The antisense sequence was 5′CCATTGGGCCATCC-TGTTTCT-3′. The corresponding sense sequence, used as a control, was 5′AGAAACAGGATGGCCCAAT-GG-3′.
Quantitative RT-PCR
VEGF expression has been assessed by quantitative RT-PCR by using the Cepheid Smart Cycler (Sunnyvale, CA). Total cytoplasmic RNA was extracted from endothelial cells by using the RNeasy® Mini Kit (Qiagen, Valencia, CA). The extracted RNA was then subjected to DNAase treatment by using DNase I (Invitrogen) and Oligo dT primers (Invitrogen). Reverse transcription was then obtained by using the Omniscript™ RT Kit (Qiagen) following the manufacturer's instructions. Primers were designed (with the online MIT resource Primer 3 technology) to include a target sequence within exon 3 and 4 of the bovine VEGF gene (accession # M32976) and to generate a PCR product of 138 bp. The primers (Left 5′ ATTTTCAAG CCGTCCTGTGT 3′) and (Right 5′TATGTGCTGGCTTTGG TGAG 3′) were obtained from the Molecular Biology Core Laboratory of the Medical College of Georgia. The PCR reaction was performed by using LightCycler FastStart DNA Master SYBR Green I enzyme mix (Roche, Indianapolis, IN). The cycling parameters were optimized as follows: start 95°C for 2 min; denaturing 95°C for 5 s; annealing 64°C for 30 s; elongating 72°C for 10 s; repeated for 40 cycles. Standard curves were created by using serial dilution of the bovine VEGF amplicon purified from a 1.2% agarose gel with Qiaex® II Gel Extraction Kit (Qiagen) and quantified spectrophotometrically. The VEGF amplification values were normalized versus rates of internal standard amplification. As an internal standard (housekeeper gene), we used bovine acidic ribosomal protein 1 (ARP), (accession # AF013214), using primers (Left 5′ TACACC TTCCCACTTGCTGA 3′) and (Right 5′ CTCCGACTCCTCCTTTGCTT 3′) obtained from the Molecular Biology Core Laboratory of the Medical College of Georgia.
RESULTS
VEGF induces rapid STAT3 tyrosine phosphorylation and nuclear translocation in BREC
BREC stimulation with 10 ng/ml of VEGF resulted in a rapid STAT3 tyrosine phosphorylation, as assessed by Western blotting analysis (Fig. 1a) with anti-phosphotyrosine STAT3 antibody. Phospho STAT3 immunoreactivity was detected within 5 min and up to 30 min after VEGF stimulation. Because we have previously found that STAT3 tyrosine phosphorylation in BAEC is not followed by its nuclear translocation (22) , we wanted to determine whether VEGF stimulation in BREC results in STAT3 mobilization to the nuclear compartment. STAT3-specific immunoreactivity was detected in both immunoblotted purified nuclear extracts (Fig. 1b) and, by confocal microscopy, in BREC's nuclei (Fig. 2) . STAT3 appeared to be translocated to the nucleus as early as 5 min after VEGF treatment (Fig. 1b and 2b) . Peaks of nuclear STAT3 immunoreactivity were detected 15 min after VEGF stimulation (Fig. 1b and 2c, respectively) .
VEGF promotes STAT3/VEGFR2 complex formation in BREC and not in BAEC
Nuclear translocation of STAT proteins requires their interaction with "shuttle" molecules bearing a nuclear localization signal (NLS; 26). Previous works have shown that VEGFR2 possess a NLS and is rapidly translocated to the nuclear compartment of endothelial cells in response to VEGF stimulation (23) . To determine whether STAT3/VEGFR2 association is correlated with STAT3′s different activation pathways in BAEC and in BREC, we performed coprecipitation experiments to assess the presence of this complex in the two endothelial cell types. In BREC, specific immunoreactivity for VEGFR2 was detected in STAT3-immunoprecipitates from the control and VEGF-treated BREC (Fig. 3a) . After VEGF stimulation, the STAT3/VEGFR2 complex signal was decreased at 5 min and almost undetectable at 15 min. At this time STAT3 immunoreactivity peaked in the nucleus of activated BREC (as shown in Fig.  1b and 2c) . The same STAT3/VEGFR2 association pattern was also detected by immunoblotting STAT3 in VEGFR2-immunoprecipitates, as shown in Fig. 3b . These experiments were also performed in BAEC, where we have previously found that after VEGF stimulation STAT3 nuclear translocation does not occur (22) . In this endothelial cell type we did not detect STAT3 immunoreactivity in VEGFR2 immunoprecipitates or vice versa (data not shown), indicating that these two proteins do not form a complex.
VEGF-dependent VEGF expression is greatly enhanced in BREC and not in BAEC
Our results so far indicated that STAT3 displays a differential ability to form a complex with VEGFR2 and to be translocated to the nuclear compartment in BREC. We wanted to determine whether this different STAT3 activation pattern could result in diverse STAT3-dependent transcriptional events, such as VEGF expression. VEGFR2-mediated induction of VEGF autocrine expression has been shown to be important in brain cancers and in inflammatory disease (7, 27) .
Quantitative real-time RT-PCR was performed to measure VEGF-specific RNA formation in BAEC and BREC upon VEGF induction. In microvascular BREC (black bars of Fig. 4) , VEGF gene expression is stimulated, twofold increase vs. control, by treatment with 25 ng/ml VEGF. Maximal stimulation is observed 1 h after VEGF induction, is decreased at 2 h, and returns to the basal conditions 3 h later (black bars of Fig. 4) . By contrast, BAEC subjected to the same treatment did not respond by up-regulating VEGF gene transcription at any of these tested times (white bars of Fig. 4) . Furthermore, prolonged exposure (overnight) of BAEC to VEGF stimulation was still ineffective in inducing VEGF production in this endothelial cell type (data not shown).
VEGF-induced VEGF expression in BREC is STAT3-dependent
To show that STAT3 is playing a significant role in inducing VEGF autocrine expression in BREC, we used a lack-of-function approach. STAT3 function inhibition was obtained by reducing its bio-availability with a specific antisense oligonucleotide. Hypertonic loading of 1 µM phosphorothioate antisense oligonucletides in BREC resulted in 75% reduction of STAT3 protein level, as measured by Western blotting analysis performed 24 h after antisense transfection (Fig. 5) . The same effect was not observed in BREC treated with the sense construct or subjected to hypertonic shock only (control samples) (Fig. 5) . Decreased STAT3 bioavailability, as obtained by the antisense treatment, significantly inhibited BREC ability to induce VEGF expression in an autocrine fashion after 1 h treatment (AS+V of Fig. 6 ). At the same time VEGF gene transcription was significantly induced in the sense treated (S+V in Fig.  6 ) and in the control-treated cells (C+V of Fig. 6 ). These data confirm that STAT3 is a major mediator of VEGF expression induced by autocrine stimulation of BREC. Thus differences of STAT3 activation pattern, as observed in BAEC and BREC, explain the observed differences in VEGF expression.
VEGF autocrine expression is correlated with STAT3 activation in HDMEC
To determine whether STAT3 may also be involved in VEGF's ability to induce its own expression in other microvascular endothelial cells, we studied the effects of VEGF on VEGF autocrine expression and STAT3 activation in HDMEC. VEGF stimulation (25 ng/ml) of cultured HDMEC resulted in the induction of VEGF expression that peaked 3 h after treatment, as assessed by quantitative real-time RT-PCR and illustrated in Fig. 7 . Furthermore, VEGF stimulation of HDMEC also resulted in rapid STAT3 tyrosine phosphorylation, 5 min after treatment, as determined by Western blotting analysis and shown in Fig. 8 .
DISCUSSION
We have shown previously that in macrovascular aortic endothelial cells, VEGF induces STAT1 and STAT6 activation, but STAT3 tyrosine phosphorylation is a late and transient event not followed by its nuclear translocation (22) , thus implying lack of STAT3-dependent gene expression. Because angiogenesis primarily targets microvascular structure, we wanted to determine whether the pattern of STAT3 activation in response to VEGF stimulation could be different in microvascular endothelial cells.
In this study we found that in retinal microvascular endothelial cells, which are important targets of pathological angiogenesis, VEGF induces a rapid STAT3 tyrosine phosphorylation and nuclear translocation. Furthermore, we found that VEGF's differential ability to induce STAT3 full activation in BREC correlates with STAT3/VEGFR2 complex formation. STAT protein mobilization into the nucleus is an active process that requires interaction with the "importin system" (26) . STAT proteins do not possess a NLS and are shuttled in the nuclear compartment by carrier molecules bearing a NLS (26) . Tyrosine kinase growth factor receptors have been shown to have this ability (28) . VEGFR2 possess a NLS and has been shown to migrate to the nucleus of the activated cells within specialized plasma membrane compartments called caveolae (23) .
Because STAT3 is nuclear translocated only in BREC, where it is also associated with VEGFR2, our data strongly suggest that VEGFR2 mediates STAT3 nuclear translocation. This hypothesis is also supported by the recent observation that, in cytokine signaling, STAT3 localizes within the caveolar compartment and this sub-cellular localization appears to determine STAT3 transcriptional activity (29) . Further studies will be necessary to understand the molecular determinants of STAT3/VEGFR2 complex formation in BREC and in BAEC. Interestingly, some authors have shown that the disruption of intercellular adherens junctions in BAEC triggers proliferation and autocrine production of VEGF (30) . This suggests to us that rearrangements of adhesion proteins could influence STAT3/VEGFR2 association and could then be involved in the differences observed in BREC versus BAEC.
Increased VEGF production is a trademark of several pathological conditions characterized by abnormal angiogenesis (1, 4-6 ). The transcriptional events leading to VEGF gene expression in such pathologies are not completely understood. Recently, it has been shown that the transcription factor STAT3 plays a major role in angiogenesis by mediating VEGF expression (7, (12) (13) (14) (15) . In this study we tested the biological effects of VEGF-dependent STAT3 differential activation in BAEC and BREC by comparing VEGF's autocrine ability to induce its own expression in these two endothelial cell types. Our results indicate that, indeed, VEGF autocrine production is stimulated only in BREC and not in BAEC. We have also demonstrated that VEGF autocrine induction in BREC is a STAT3-dependent effect, thus confirming that differential STAT3 activation patterns result in different biological responses of the two endothelial cell types. This is also supported by the results obtained in HDMEC in which the induction of VEGF autocrine expression is accompanied by STAT3 tyrosine phosphorylation following a pattern very similar to the one observed in BREC and not in BAEC.
The relevance of our findings, which are summarized in Fig. 9 , is the identification of STAT3 as a specific mediator of biological responses of micro-vascular endothelial cells and as a major player of VEGF autocrine production. The first aspect particularly applies to those pathological situations in which systemic anti-angiogenic therapies may negatively affect macro-vascular structures. This is the case of diabetic vasculopathy, which targets macro-and micro-vascular districts in opposing ways. The second aspect finds its application in tumor biology, where VEGF autocrine activity has a relevant impact in tumor angiogenesis and tumor progression (7, 15, 31, 32) . Everything considered, our study provides further support to the importance of STAT3 as a pharmacological target for the therapeutic management of pathological angiogenesis. 
